RESEARCHER PROFILE (Filmed November 2023)
Dr Felicity Han, Research Fellow
Australian Institute for Bioengineering and Nanotechnology
University of Queensland, Australia
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
Dr Han’s team have developed five different techniques to produce painkiller-loaded nanoparticles and nanofibers aimed at improving pain relief for patients where available pain-killers either lack efficacy or produce dose-limiting side-effects. With the use of their nanoparticles, Dr Han’s team aim to turn a small but potent peptide that has been on the market for over a decade into an oral treatment for improving pain management that currently lacks efficacy in patients. T
Dr Han’s research focuses on developing drug-products to solve one of the largest unmet medical needs in the pain field through the use of sustainable materials. Her team are currently working on developing multifunctional sutures including biodegradable pain relief sutures and innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. Their research also investigates the role of C5a and C3a in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain, and OA pain.
Dr Han works in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. They also provide a preclinical evaluation of novel compounds and formulations.
Dr Han enjoy’s volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). Currently, she is serving as a guest editor of Pain Research and Management.
You Might also like
-
Big data to improve the use of antidepressant medicines in aged care
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Anaemia guidelines updated after 50 years
Professor Sant-Rayn Pasricha is the Acting Deputy Director at the Walter Eliza Hall Institute of Medical Research in Melbourne, Australia. He is also a clinical haematologist at the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. From a young age, Prof Pasricha dreamed of becoming a doctor and found joy in learning about the human body and how to care for patients. After completing medical school, he developed a passion for working in low and middle-income countries, which led him to spend time working in East Timor, India, and Central Australia with First Nations communities.